 The aim of this pilot study is to correlate the sorafenib plasma concentration to observed toxicity and to the disease control rate in 100 patients undergoing a palliative treatment of hepatocellular carcinoma HCC. If some correlations are observed, we will consider planning a larger interventional study to adjust sorafenib daily dose to plasma concentration. 